Joel Burwell, PA
Family Medicine · Gulfport, MSNPI 1427012657
Payments from drug & device makers
Across 367 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$638
- Lilly USA, LLC$609
- GSK$427
- Pfizer$397
- Amgen$296
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,886100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 86 | $1,218 |
| AstraZeneca | 36 | $638 |
| Lilly USA, LLC | 38 | $609 |
| GSK | 40 | $427 |
| Pfizer | 27 | $397 |
| Amgen | 11 | $296 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $246 |
| Novo Nordisk | 13 | $199 |
| Abbott | 8 | $154 |
| Mylan Specialty L.p. | 8 | $146 |
| Sumitomo Pharma America, Inc. | 8 | $135 |
| Antares Pharma, Inc. | 6 | $132 |
| Xeris Pharmaceuticals, Inc. | 6 | $127 |
| Astellas Pharma US Inc | 8 | $124 |
| Boehringer Ingelheim | 8 | $122 |
| Neuronetics, Inc. | 1 | $121 |
| Viatris Specialty LLC | 4 | $84 |
| Acerus Pharmaceuticals Corporation | 5 | $83 |
| Lundbeck LLC | 4 | $76 |
| Kowa Pharmaceuticals America, Inc. | 5 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Jazz Pharmaceuticals Inc. | 3 | $56 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Tolmar, Inc. | 3 | $47 |
| Shire North American Group Inc | 3 | $42 |
| Novartis | 2 | $42 |
| Exact Sciences | 2 | $32 |
| Johnson & Johnson | 2 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 2 | $18 |
| Averitas Pharma Inc. | 1 | $18 |
| GRT US Holding, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$122
- NEUROSTAR TMS THERAPY$121
How this compares
$5,886 in reported general payments places this provider in the 85th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $113,150 |
| JardianceEmpagliflozin | 75 | $86,912 |
| Tresiba Flextouch U-200Insulin Degludec | 69 | $58,013 |
| EliquisApixaban | 51 | $46,359 |
| JanuviaSitagliptin Phosphate | 38 | $45,983 |
| TrulicityDulaglutide | 22 | $45,907 |
| MounjaroTirzepatide | 23 | $25,562 |
| MyrbetriqMirabegron | 26 | $23,960 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $21,182 |
| EntrestoSacubitril/Valsartan | 13 | $19,142 |
| FarxigaDapagliflozin Propanediol | 16 | $18,399 |
| LinzessLinaclotide | 20 | $13,219 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $10,530 |
| TrintellixVortioxetine Hydrobromide | 13 | $8,993 |
| Xigduo XrDapaglifloz Propaned/Metformin | 15 | $6,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $199 | $113,15095 claims |
| Boehringer IngelheimJardiance | $122 | $86,91275 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $609 | $71,46945 claims |
| PfizerEliquis | $397 | $46,35951 claims |
| MerckJanuvia | $14 | $45,98338 claims |
| AstraZenecaFarxiga, Symbicort | $638 | $28,92951 claims |
| Astellas Pharma US IncMyrbetriq | $124 | $23,96026 claims |
| GSKTrelegy Ellipta | $427 | $21,18228 claims |
| NovartisEntresto | $42 | $19,14213 claims |
| AbbVieLinzess, Synthroid | $1,218 | $16,65356 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $246 | $8,99313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Gulfport
- Paul MatherneGulfport$14.4M
- Sean KerbyGulfport$6.6M
- Kathy KeimigGulfport$20K
- Jonathan HamiltonGulfport$16K
- Dimitrios DimitriadesGulfport$13K
- Steven SchepensGulfport$12K
- Matthew BosargeGulfport$10K
- Timothy QuinnRidgeland$8M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.